KRAS and colorectal cancer: The present study attempts to explore the inhibitory impact of KA25 and KA39 derivatives on Akt1 and Akt2 phosphorylation in three colorectal cancer cell lines (HT-29, LoVo, and SW403) with specific PIK3CA and KRAS statuses (Table 6).